Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) CEO Vlad Coric sold 150,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.41, for a total transaction of $4,411,500.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

TRADEMARK VIOLATION NOTICE: “Vlad Coric Sells 150,000 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/vlad-coric-sells-150000-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.

Several brokerages recently issued reports on BHVN. BidaskClub lowered shares of Biohaven Pharmaceutical Holding Co from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. William Blair restated an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, October 3rd. Morgan Stanley reiterated an “overweight” rating and issued a $38.00 price target (down from $47.00) on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, October 3rd. Finally, Needham & Company LLC dropped their price target on shares of Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $40.80.

Several hedge funds and other institutional investors have recently modified their holdings of BHVN. Nationwide Fund Advisors acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $214,000. State of Wisconsin Investment Board acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $262,000. Deschutes Portfolio Strategy LLC acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $374,000. Strs Ohio acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $680,000. Finally, American Century Companies Inc. acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $1,375,000.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.